Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the ...

Speaking at the J.P. Morgan Healthcare Conference, Doustdar said compounders recognized consumer behavior earlier than major ...

Novo Nordisk CEO Mike Doustdar highlighted the growing use of compounded GLP-1 drugs in the U.S., which are cheaper but ...

Novo Nordisk CEO Mike Doustdar highlighted the growth of compounded GLP-1 drug versions in the U.S. market, capturing 1.5 ...

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...

NEW YORK/LONDON, Nov 12 (Reuters) - When Novo Nordisk (NOVOb.CO), opens new tab CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer (PFE.N), ...

COPENHAGEN (Reuters) -Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill, as the firm ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

People turning to injectable GLP-1 treatments—a class of drugs that mimics that hormone to control diabetes and promote weight loss—now have another way to take the medication. On Dec. 22, the U.S.

Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo ...

NEW YORK/LONDON (Reuters) -When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer, he was not ready to give up just yet on the ...